Harrison Hayes Creates Angel Fund to Invest in Emerging Life Science Firms

Based on our broad contacts throughout the life sciences industry, we have made the decision to put together an Angel Fund that will invest up to $250,000 per transaction in emerging life science technology companies. We will invest in firms whose technologies and products are applicable across a wide range of segments including human healthcare therapeutics and diagnostics/devices; health/wellness; agricultural biotechnology; material science and industrial biotechnology (biomaterials/bioprocesses).

We employ a flexible investment approach to working with management and vendors and aim to align interests to the benefit of all. In our deals, management will have a significant financial stake in the company.

Harrison Hayes' success is founded on building long-term relationships with entrepreneurs and portfolio companies. Over two decades of experience identifying, validating and backing emerging trends and technologies will provide our portfolio companies strategic advantages essential to success.

Please contact us at for an initial review. The further evaluation of the business proposals will be based on supporting technical materials such as an executive summary, business plan or investment memorandum.